N1L is an ectromelia virus virulence factor and essential for in vivo spread upon respiratory infection

Journal of Virology

Volumn 85, Issue 7, 2011, Pages 3557-3569

  Gratz, Meike S ^a   Suezer, Yasemin ^a   Kremer, Melanie ^b   Volz, Asisa ^b   Majzoub, Monir ^b   Hanschmann, Kay Martin ^a   Kalinke, Ulrich ^a,c   Schwantes, Astrid ^a   Sutter, Gerd ^a,b  

^a PAUL EHRLICH INSTITUT   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c INSTITUTE OF INFECTION IMMUNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON RECEPTOR; PROTEIN N1L; RIG I LIKE RNA HELICASE; RNA HELICASE; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; VIRULENCE FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; ECTROMELIA VIRUS; FEMALE; IN VIVO STUDY; LIVER; LUNG; MOUSE; MOUSEPOX; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SPLEEN; T LYMPHOCYTE; VIRAL RESPIRATORY TRACT INFECTION; VIROGENESIS; VIRUS LOAD; VIRUS MUTANT; VIRUS REPLICATION;

ANIMALS; BODY WEIGHT; ECTROMELIA VIRUS; ECTROMELIA, INFECTIOUS; FEMALE; GENE DELETION; HISTOCYTOCHEMISTRY; IMMUNE TOLERANCE; LIVER; LUNG; MICE; MICE, INBRED C57BL; RESPIRATORY TRACT INFECTIONS; SPLEEN; SURVIVAL ANALYSIS; T-LYMPHOCYTES; VIRAL LOAD; VIRAL PROTEINS; VIRULENCE FACTORS;

ECTROMELIA VIRUS; MUS; ORTHOPOXVIRUS; VACCINIA VIRUS;

EID: 79952590431     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01191-10     Document Type: Article

References (74)

1. Alcami, A. 2003. Viral mimicry of cytokines, chemokines and their receptors. Nat. Rev. Immunol. 3:36-50.
2. Aoyagi, M., et al. 2007. Vaccinia virus N1L protein resembles a B cell lymphoma-2 (Bcl-2) family protein. Protein Sci. 16:118-124. (Pubitemid 46036504)
3. Bartlett, N., J. A. Symons, D. C. Tscharke, and G. L. Smith. 2002. The vaccinia virus N1L protein is an intracellular homodimer that promotes virulence. J. Gen. Virol. 83:1965-1976.
4. + dendritic cell subpopulations following pulmonary poxvirus infection. J. Virol. 84:10191-10199.
5. + T cell responses following pulmonary DNA immunization. J. Virol. 84:5764-5774.
6. Born, T. L., et al. 2000. A poxvirus protein that binds to and inactivates IL-18, and inhibits NK cell response. J. Immunol. 164:3246-3254. (Pubitemid 30148988)
7. Bowie, A., et al. 2000. A46R and A52R from vaccinia virus are antagonists of host IL-1 and toll-like receptor signaling. Proc. Natl. Acad. Sci. U. S. A. 97:10162-10167.
8. Boyle, D. B., and B. E. H. Coupar. 1988. A dominant selectable marker for the construction of recombinant poxviruses. Gene 65:123-128.
9. Bray, M., et al. 2000. Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge. J. Infect. Dis. 181:10-19.
10. Breman, J. G., and D. A. Henderson. 2002. Diagnosis and management of smallpox. N. Engl. J. Med. 346:1300-1308.
11. Brick, D. J., R. D. Burke, A. A. Minkley, and C. Upton. 2000. Ectromelia virus virulence factor p28 acts upstream of caspase-3 in response to UV light-induced apoptosis. J. Gen. Virol. 81:1087-1097.
12. Chaudhri, G., V. Panchanathan, H. Bluethmann, and G. Karupiah. 2006. Obligatory requirement for antibody in recovery from a primary poxvirus infection. J. Virol. 80:6339-6344. (Pubitemid 43927437)
13. Chen, N., R. M. Buller, E. M. Wall, and C. Upton. 2000. Analysis of host response modifier ORFs of ectromelia virus, the causative agent of mouse-pox. Virus Res. 66:155-173. (Pubitemid 30139489)
14. Cooray, S., et al. 2007. Functional and structural studies of the vaccinia virus virulence factor N1 reveal a Bcl-2-like anti-apoptotic protein. J. Gen. Virol. 88:1656-1666.
15. Cordeiro, J., et al. 2009. F11-mediated inhibition of RhoA signalling enhances the spread of vaccinia virus in vitro and in vivo in an intranasal mouse model of infection. PLoS One 4:e8506.
16. Dénes, B., et al. 2006. Attenuation of a vaccine strain of vaccinia virus via inactivation of interferon viroceptor. J. Gene Med. 8:814-823. (Pubitemid 44097137)
17. Di Giulio, D. B., and P. B. Eckburg. 2004. Human monkeypox: an emerging zoonosis. Lancet Infect. Dis. 4:15-25.
18. DiPerna, G., et al. 2004. Poxvirus protein N1L targets the I-κB kinase complex, inhibits signaling to NF-κB by the tumor necrosis factor superfamily of receptors, and inhibits NF-κB and IRF3 signaling by Toll-like receptors. J. Biol. Chem. 279:36570-36578.
19. Essbauer, S., M. Pfeffer, and H. Meyer. 2010. Zoonotic poxviruses. Vet. Microbiol. 140:229-236.
20. Esteban, D. J., and R. M. Buller. 2005. Ectromelia virus: the causative agent of mousepox. J. Gen. Virol. 86:2645-2659.
21. Falkner, F. G., and B. Moss. 1990. Transient dominant selection of recombinant vaccinia viruses. J. Virol. 64:3108-3111. (Pubitemid 20171312)
22. Fang, M., L. L. Lanier, and L. J. Sigal. 2008. A role for NKG2D in NK cell-mediated resistance to poxvirus disease. PLoS Pathog. 4:e30.
23. Fenner, F. 1948. The clinical features and pathogenesis of mouse-pox (infectious ectromelia of mice). J. Pathol. Bacteriol. 60:529-552.
24. Fenner, F., D. A. Henderson, I. Arita, Z. Jezek, and I. D. Ladnyi. 1988. Smallpox and its eradication. World Health Organization, Geneva, Switzerland.
25. Fenner, F. 1949. Mouse-pox (infectious ectromelia of mice): a review. J. Immunol. 63:341-373.
26. Finlay, B. B., and G. McFadden. 2006. Anti-immunology: evasion of the host immune system by bacterial and viral pathogens. Cell 124:767-782. (Pubitemid 43261451)
27. Fischer, S. F., et al. 2006. Modified vaccinia virus Ankara protein F1L is a novel BH3-domain-binding protein and acts together with the early viral protein E3L to block virus-associated apoptosis. Cell Death Differ. 13:109-118.
28. Garcia, M. A., S. Guerra, J. Gil, V. Jimenez, and M. Esteban. 2002. Anti-apoptotic and oncogenic properties of the dsRNA-binding protein of vaccinia virus, E3L. Oncogene 21:8379-8387. (Pubitemid 36054880)
29. Gu, H., Y. R. Zou, and K. Rajewsky. 1993. Independent control of immunoglobulin switch recombination at individual switch regions evidenced through Cre-loxP-mediated gene targeting. Cell 73:1155-1164. (Pubitemid 23180489)
30. Gubser, C., S. Hue, P. Kellam, and G. L. Smith. 2004. Poxvirus genomes: a phylogenetic analysis. J. Gen. Virol. 85:105-117.
31. Hornung, V., et al. 2009. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature 458:514-518.
32. Horton, R. M., H. D. Hunt, S. N. Ho, J. K. Pullen, and L. R. Pease. 1989. Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension. Gene 77:61-68.
33. Jacobs, N., N. W. Bartlett, R. H. Clark, and G. L. Smith. 2008. Vaccinia virus lacking the Bcl-2-like protein N1 induces a stronger natural killer cell response to infection. J. Gen. Virol. 89:2877-2881.
34. Jacoby, R. O., P. N. Bhatt, and D. G. Brownstein. 1989. Evidence that NK cells and interferon are required for genetic resistance to lethal infection with ectromelia virus. Arch. Virol. 108:49-58.
35. Johnston, J. B., and G. McFadden. 2003. Poxvirus immunomodulatory strategies: current perspectives. J. Virol. 77:6093-6100. (Pubitemid 36588380)
36. Jonjic, S., M. Babic, B. Polic, and A. Krmpotic. 2008. Immune evasion of natural killer cells by viruses. Curr. Opin. Immunol. 20:30-38.
37. + T lymphocytes and macrophage subsets in the control of a generalized virus infection. J. Virol. 70:8301-8309.
38. Karupiah, G., T. N. Fredrickson, K. L. Holmes, L. H. Khairallah, and R. M. Buller. 1993. Importance of interferons in recovery from mousepox. J. Virol. 67:4214-4226.
39. + T cells. Science 248:1227-1230.
40. Kotwal, G. J., A. W. Hugin, and B. Moss. 1989. Mapping and insertional mutagenesis of a vaccinia virus gene encoding a 13,800-Da secreted protein. Virology 171:579-587. (Pubitemid 19210402)
41. Kotwal, G. J., and M.-R. Abrahams. 2004. Growing poxviruses and determining virus titer. Methods Mol. Biol. 269:101-112.
42. Kumar, H., et al. 2006. Essential role of IPS-1 in innate immune responses against RNA viruses. J. Exp. Med. 203:1795-1803.
43. Legrand, F. A., et al. 2004. Induction of potent humoral and cell-mediated immune responses by attenuated vaccinia virus vectors with deleted serpin genes. J. Virol. 78:2770-2779. (Pubitemid 38314336)
44. Loparev, V. N., et al. 1998. A third distinct tumor necrosis factor receptor of orthopoxviruses. Proc. Natl. Acad. Sci. U. S. A. 95:3786-3791.
45. Lorenzo, M. M., I. Galindo, and R. Blasco. 2004. Construction and isolation of recombinant vaccinia virus using genetic markers. Methods Mol. Biol. 269:15-30.
46. Martinez, M. J., M. P. Bray, and J. W. Huggins. 2000. A mouse model of aerosol-transmitted orthopoxviral disease. Arch. Pathol. Lab. Med. 124:362-377.
47. Masopust, D., V. Vezys, A. L. Marzo, and L. Lefrancois. 2001. Preferential localization of effector memory cells in nonlymphoid tissue. Science 291:2413-2417. (Pubitemid 32231804)
48. Mathew, A., et al. 2008. Robust intrapulmonary CD8 T cell responses and protection with an attenuated N1L deleted vaccinia virus. PLoS One 3:e3323.
49. McFadden, G. 2005. Poxvirus tropism. Nat. Rev. Microbiol. 3:201-213.
50. Mombaerts, P., et al. 1992. RAG-1-deficient mice have no mature B and T lymphocytes. Cell 68:869-877.
51. Montasir, M., E. R. Rabin, and C. A. Phillips. 1966. Vaccinia pneumonia in mice: a light and electron microscopic and viral assay study. Am. J. Pathol. 48:877-895.
52. Muller, U., et al. 1994. Functional role of type I and type II interferons in antiviral defense. Science 264:1918-1921. (Pubitemid 24245635)
53. Panchanathan, V., G. Chaudhri, and G. Karupiah. 2006. Protective immunity against secondary poxvirus infection is dependent on antibody but not on CD4 or CD8 T-cell function. J. Virol. 80:6333-6338. (Pubitemid 43927436)
54. Paran, N., et al. 2009. Postexposure immunization with modified vaccinia virus Ankara or conventional Lister vaccine provides solid protection in a murine model of human smallpox. J. Infect. Dis. 199:39-48.
55. Parker, A. K., S. Parker, W. M. Yokoyama, J. A. Corbett, and R. M. Buller. 2007. Induction of natural killer cell responses by ectromelia virus controls infection. J. Virol. 81:4070-4079.
56. Rathinam, V. A. K., et al. 2010. The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses. Nat. Immunol. 11:395-402.
57. Rimoin, A. W., et al. 2010. Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proc. Natl. Acad. Sci. U. S. A. 107:16262-16267.
58. Samuelsson, C., et al. 2008. Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection. J. Clin. Invest. 118:1776-1784.
59. Seet, B. T., et al. 2003. Poxviruses and immune evasion. Annu. Rev. Immunol. 21:377-423.
60. Senkevich, T. G., E. V. Koonin, and R. M. Buller. 1994. A poxvirus protein with a RING zinc finger motif is of crucial importance for virulence. Virology 198:118-128.
61. Smee, D. F., K. W. Bailey, and R. W. Sidwell. 2001. Treatment of lethal vaccinia virus respiratory infections in mice with cidofovir. Antivir. Chem. Chemother. 12:71-76.
62. Smith, G. L. 1999. Vaccinia virus immune evasion. Immunol. Lett. 65:55-62.
63. Smith, G. L., J. A. Symons, A. Khanna, A. Vanderplasschen, and A. Alcami. 1997. Vaccinia virus immune evasion. Immunol. Rev. 159:137-154.
64. Smith, V. P., and A. Alcami. 2000. Expression of secreted cytokine and chemokine inhibitors by ectromelia virus. J. Virol. 74:8460-8471. (Pubitemid 30666696)
65. Staib, C., M. Löwel, V. Erfle, and G. Sutter. 2003. Improved host range selection for recombinant modified vaccinia virus Ankara. Biotechniques 34:694-696, 698, 700.
66. Stanford, M. M., G. McFadden, G. Karupiah, and G. Chaudhri. 2007. Immunopathogenesis of poxvirus infections: forecasting the impending storm. Immunol. Cell Biol. 85:93-102.
67. Takaoka, A., et al. 2007. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature 448:501-505. (Pubitemid 47123520)
68. Thompson, A. J., and S. A. Locarnini. 2007. Toll-like receptors, RIG-I-like RNA helicases and the antiviral innate immune response. Immunol. Cell Biol. 85:435-445.
69. Thompson, J. P., P. C. Turner, A. N. Ali, B. C. Crenshaw, and R. W. Moyer. 1993. The effects of serpin gene mutations on the distinctive pathobiology of cowpox and rabbitpox virus following intranasal inoculation of Balb/c mice. Virology 197:328-338.
70. Waibler, Z., et al. 2007. Modified vaccinia virus Ankara induces Toll-like receptor-independent type I interferon responses. J. Virol. 81:12102-12110. (Pubitemid 350085825)
71. Wang, Z., et al. 2008. Regulation of innate immune responses by DAI (DLM-1/ZBP1) and other DNA-sensing molecules. Proc. Natl. Acad. Sci. U. S. A. 105:5477-5482.
72. Wasilenko, S. T., T. L. Stewart, A. F. Meyers, and M. Barry. 2003. Vaccinia virus encodes a previously uncharacterized mitochondrial-associated inhibitor of apoptosis. Proc. Natl. Acad. Sci. U. S. A. 100:14345-14350.
73. Yamamoto, M., et al. 2003. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 301:640-643. (Pubitemid 36927946)
74. + cytolytic T cells. Nature 344:742-746.